In situ injectable lyotropic liquid crystal depot for sustained taphalgin release in acute postsurgical pain management

Published on March 30, 2026

Int J Pharm. 2026 Mar 24:126810. doi: 10.1016/j.ijpharm.2026.126810. Online ahead of print.

ABSTRACT

Acute postsurgical pain (APSP) poses significant pain management challenges in clinical due to limitations of current analgesics in efficacy or safety. This study developed an in situ injectable lyotropic liquid crystal (LLC) depot for sustained release of Taphalgin (TAP), a tetrapeptide agonist of μ1-opioid receptors with potent analgesia and low side effects. A TAP-loaded hexagonal phase liquid crystalline (TAP/EG-LLC-Gel) was constructed by the self-assembly of glyceryl monooleate (GMO) and egg yolk phosphatidylcholine (EYPC) via solvent exchange of propylene glycol with aqueous solution, characterized through polarized light microscopy (PLM), small-angle X-ray scattering (SAXS), and rheological analysis. This TAP/EG-LLC-Gel demonstrated a cumulative release of 57.0 ± 2.6% (8 days) with mild initial burst release of 6.6 ± 1.8% (8 h), indicating favorable sustained release behaviors for TAP. Compared to free TAP, pharmacokinetic analysis revealed a 78-fold prolonged half-life (110.39 ± 30.10 h) for TAP/EG-LLC-Gel. The analgesic activity of TAP-LLC was evaluated in animal models of incision pain and acetic acid writhing, showing long-acting dose-dependent analgesia up to 8 days. This TAP-loaded in situ injectable LLC depot showed excellent sustained release behaviors with potent, long-acting and dose-dependent analgesia in two animal pain models, offering a promising solution for APSP management.

PMID:41887274 | DOI:10.1016/j.ijpharm.2026.126810

Continue reading on website
Other news

Risk Stratification and Neck Pain Management in Office Workers Using Rapid Upper Limb Assessment

March 30, 2026
Musculoskeletal Care. 2026 Mar;24(1):e70208. doi: 10.1002/msc.70208.ABSTRACTBACKGROUND: The present study aimed to identify the role Rapid Upper Limb Assessment (RULA) for the assessment of office worker's ergonomics in the workplace and its efficacy in designing targeted interventions with a specific focus on neck pain.METHODS: Sixty six office workers (Mean Age = 33.04 ± 9.98 years; Mean BMI = 2

A Qualitative Study Examining Barriers to Buprenorphine for Pain Management in Patients with End Stage Kidney Disease Undergoing Hemodialysis

March 30, 2026
J Pain. 2026 Mar 24:106269. doi: 10.1016/j.jpain.2026.106269. Online ahead of print.ABSTRACTChronic pain is common and burdensome among people with end stage kidney disease (ESKD). Pain management options are limited and prescription opioids are often used in this population, but carry unwanted risks (e.g., side effects, misuse, overdose). Buprenorphine is increasingly viewed as a safer alternativ